| MDD; OCD; panic disorder; PTSD; social anxiety disorder. View labelExact | Start 50 mg once daily for major depressive disorder (clinical depression) or anxiety; titrate by 25–50 mg increments every ≥1 week to 100–200 mg/day (max 200 mg/day). | Selective serotonin reuptake inhibitor (SSRI). | Multiple CYPs | Steady-state mean 26 h | No | — | - Suicidality and psychiatric activation during initiation and dose changes, especially in younger patients and in bipolar-spectrum illness.
- Sodium in older adults or patients on diuretics if symptoms suggest hyponatremia (confusion, fatigue, falls).
- Bleeding/bruising risk when combined with NSAIDs, antiplatelets, or anticoagulants; reinforce early symptom reporting.
- Medication reconciliation when TCAs, antipsychotics, or other serotonergic agents are co-prescribed; anticipate switching washout needs when regimens change.
| No | 2025-12-28 |
|---|
| Major depressive disorder; generalized anxiety disorder. View labelExact | Typical adult start is 10 mg once daily; may increase to 20 mg/day after ≥1 week if needed and tolerated. | Selective serotonin reuptake inhibitor (SSRI). | CYP2C19, CYP2D6 (minor), CYP3A4 (minor) | Single-dose mean 27 h; Single-dose range 27–32 h; Steady-state mean 30 h | No | — | - Suicidality and psychiatric activation (anxiety, agitation, mood elevation) during initiation and dose changes, especially in younger patients.
- Sodium in older adults or patients on diuretics if symptoms suggest hyponatremia.
- Bleeding/bruising risk when combined with NSAIDs, antiplatelets, or anticoagulants; reinforce early symptom reporting.
- Medication reconciliation to avoid serotonergic combinations and to anticipate washout needs during antidepressant switching.
- ECG when cardiac risk is present or when combining multiple QT-active medications, even though escitalopram’s QT effect is typically smaller than citalopram.
| No | 2026-02-12 |
|---|
| Major depressive disorder; generalized anxiety disorder; social anxiety disorder; panic disorder. View labelExact | Initiate XR 37.5 mg once daily with food for 4–7 days, then 75 mg/day; increase by 75 mg increments at ≥7-day intervals up to 225 mg/day (300 mg off-label). | Serotonin-norepinephrine reuptake inhibitor (SNRI). | CYP2D6, CYP3A4 (minor), UGT | Single-dose mean 5 h; Single-dose range 4–6 h; Steady-state mean 11 h; Steady-state range 9–13 h | No | — | - Blood pressure and heart rate at baseline and after titration, with extra attention at higher doses.
- Discontinuation symptoms during missed doses or tapering; plan refill timing and taper steps proactively.
- Sodium in older adults or diuretic users if symptoms suggest hyponatremia (confusion, fatigue, falls).
- Mood elevation or agitation in bipolar-spectrum illness; coordinate prevention plans via the bipolar disorder hub.
- Medication reconciliation to avoid serotonergic combinations and to plan MAOI washouts when regimens change.
| No | 2025-10-05 |
|---|
| Major depressive disorder; generalized anxiety disorder; diabetic peripheral neuropathic pain; fibromyalgia; chronic musculoskeletal pain. View labelExact | Major depressive disorder (clinical depression) and generalized anxiety disorder: typical initiation is 30 mg once daily for one week for tolerability, then 60 mg once daily. If needed, 90–120 mg/day is sometimes used (divide when >60 mg/day), though antidepressant benefit often plateaus beyond 60 mg/day. | Serotonin-norepinephrine reuptake inhibitor (SNRI). | CYP1A2, CYP2D6 | Single-dose mean 12 h; Single-dose range 8–17 h; Steady-state mean 12 h | No | — | - Blood pressure and heart rate at baseline and periodically, especially during titration and at higher doses.
- Liver-injury symptoms (jaundice, dark urine, abdominal pain, pruritus), particularly in patients with alcohol use disorder or hepatic disease; LFTs are obtained when clinically indicated.
- Sodium in older adults or diuretic users if symptoms suggest hyponatremia (confusion, fatigue, falls).
- Medication reconciliation for serotonergic combinations and for CYP2D6 substrates (TCAs, antipsychotics, beta-blockers, tamoxifen).
| No | 2025-10-05 |
|---|